124
Participants
Start Date
August 30, 2016
Primary Completion Date
August 28, 2020
Study Completion Date
December 22, 2022
Palbociclib
125 mg, orally, daily for 3 weeks followed by 1 week off; repeated at every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
Fulvestrant
500mg, intramuscularly on days 1 and 15 of cycle 1, then on day 1 (+/- 3 days) of every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
Institut Jules Bodet, Brussels
Cliniques Universitaires Saint-Luc, Brussels
Sint-Augustinus, Antwerp
Antwerp University Hospital, Edegem
Clinique St. Elizabeth, Namur
Ospedali degli Infermi, S.O.C. Oncologia, Biella
Istituti Clinici Scientifici Maugeri, Medical Oncology Unit, Pavia
UZ Leuven, Leuven
CHU Liege, Liège
Ospedale Centrale Bolzano, Medical Oncology, Bolzano
IRCCS San Martino University Hospital, Genova
Mater Salutis Hospital AULSS 21 della Regione Veneto, Legnago
Istituto Europeo di Oncologia, Milan
Azienda USL4 Prato, Prato
Velindre NHS Trust, Cardiff
Western General Hospital, Edinburgh
Beatson West of Scotland Cancer Centre, Glasgow
Singleton Hospital, Swansea
Royal Cornwall, Truro
Collaborators (1)
Breast International Group
OTHER
ETOP IBCSG Partners Foundation
NETWORK